Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 8/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 6/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14119726 | 0.93 | CYP1A1 (0.63) | CYP1A1PKMHTR6ADRB2ADRB1 | |
| SCHEMBL14120067 | 0.86 | CYP1A1 (0.56) | CYP1A1PKMALDH1A1 | |
| SCHEMBL14217381 | 0.84 | PKM (0.54) | CYP1A1PKMALDH1A1ADRB2ADRB1 | |
| SCHEMBL14119673 | 0.83 | CYP1A1 (0.70) | CYP1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL14217385 | 0.83 | CYP1A1 (0.79) | CYP1A1PKM | |
| SCHEMBL14217387 | 0.82 | CYP1A1 (0.63) | CYP1A1ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL14119984 | 0.79 | MAPT (0.53) | CYP1A1PKMALDH1A1ADRB2ADRB1 | |
| SCHEMBL14119612 | 0.79 | ADRB2 (0.50) | CYP1A1PKMALDH1A1ADRB2ADRB1 | |
| SCHEMBL14217382 | 0.78 | ALDH1A1 (0.54) | CYP1A1ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL12353998 | 0.78 | PKM (0.61) | CYP1A1PKMADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | CYP1A1 1777/4885PKM 2928/4885HTR6 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.